根据上海证券交易所发布的上市公司分行业信息披露指引《上市公司行业 信息披露指引第六号——医药制造（2022 年修订）》及《关于做好主板上市公司 2024 年半年报报告披露工作的重要提醒》的相关要求，现将江苏吴中医药发展 股份有限公司（以下简称"公司"）主营业务 2024 年 1-6 月主要经营数据情况公 告如下： 1、2024 年 1-6 月，公司医美生科业务累计实现主营业务收入 8,011.96 万 元，较上年同期增长 7,725.24 万元，增长 2,694.30%，医美生科业务主营业务 毛利 6,640.74 万元，较上年同期增长 6,467.87 万元，增长 3,741.55%。 2、2024 年 1-6 月，公司医药业务累计实现主营业务收入 85,671.55 万元 （其中医药工业 31,968.93 万元，医药商业 53,702.62 万元），较上年同期下降 5,717.84 万元，下降 6.26%，医药业务主营业务毛利 27,191.64 万元，较上年同 期下降 1,528.86 万元，下降 5.32%。 证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-056 江苏吴中医药发 ...

证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-053 江苏吴中医药发展股份有限公司 第十一届董事会第二次会议决议公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）第十一届董事会第二 次会议通知于 2024 年 8 月 16 日以书面或电子邮件等形式发出，会议于 2024 年 8 月 27 日在公司会议室举行，会议召开方式为现场会议与通讯表决相结合的方 式。会议的召开符合《公司法》和相关法律法规以及《公司章程》《董事会议事 规则》的规定。会议应到董事 7 人，实到董事 7 人。本次会议由董事长钱群山先 生主持，公司监事会成员及高级管理人员列席了会议。会议经过讨论审议，以书 面投票表决方式通过了以下决议： 一、审议通过了江苏吴中医药发展股份有限公司 2024 年上半年总经理工作 报告 具体见公司于 2024 年 8 月 28 日在《中国证券报》《上海证券报》及上海证 券交易所网站上披露的《江苏吴中医药发展股份有限公司关于拟对外投资的公 告》。 表决结果：7 票同意 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 1,206,511,609.78, representing a 9.62% increase compared to CNY 1,100,632,396.63 in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2024 was CNY 24,454,605.15, a decrease of 10.75% from CNY 27,400,649.23 in the previous year[16]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 10,592,858.96, showing a significant increase of 417.83% compared to CNY 2,045,607.36 in the same period last year[16]. - The net cash flow from operating activities for the first half of 2024 was CNY 152,541,110.24, a substantial recovery from a negative cash flow of CNY -121,910,233.58 in the previous year[16]. - Basic earnings per share for the first half of 2024 were CNY 0.034, down 10.53% from CNY 0.038 in the same period last year[17]. - The diluted earnings per share for the first half of 2024 were also CNY 0.034, showing a decrease of 10.53% compared to the previous year[17]. - The weighted average return on net assets for the first half of 2024 was 1.392%, a slight decrease from 1.502% in the same period last year[17]. Product Development and Market Position - The net profit attributable to shareholders after deducting non-recurring gains and losses increased significantly due to the launch of the AestheFill product, generating a gross profit of RMB 66.4074 million in the medical beauty sector[18]. - The AestheFill product received regulatory approval and was officially launched in mainland China on April 22, 2024, marking a significant milestone for the company[21]. - AestheFill holds a nearly 30% market share in the regenerative injection market in Taiwan, ranking first among similar products[22]. - The company is focusing on high-end injectable products and related biomaterials, with ongoing clinical registration for new products and preclinical research for others[21]. - The pharmaceutical segment includes a diverse range of products, with key offerings in antiviral, immune regulation, and oncology fields, contributing to a robust product pipeline[21]. Financial Position and Assets - The total assets at the end of the reporting period were CNY 4,122,333,961.76, a decrease of 4.73% from CNY 4,326,878,114.57 at the end of the previous year[16]. - The net assets attributable to shareholders at the end of the reporting period were CNY 1,775,653,086.00, reflecting a 1.81% increase from CNY 1,744,014,382.12 at the end of the previous year[16]. - The company's cash and cash equivalents at the end of the reporting period amounted to ¥1,677,359,133.94, up from ¥1,511,993,492.34 at the end of the first half of 2023, showing an increase of approximately 11%[106]. - The company's total current assets decreased to approximately ¥2,936,17 million from ¥3,001.22 million, a decline of about 2.17%[94]. - The company's total liabilities decreased to ¥2,287,166,240.49, down 10.8% from ¥2,565,434,062.87[96]. Research and Development - The R&D management structure was optimized, with a focus on both chemical and biological innovative drug development[35]. - The company has established a joint laboratory for recombinant human collagen formulations with China Pharmaceutical University and Nanjing Dongwan Biotechnology, enhancing its R&D capabilities[38]. - The company is focusing on the development of innovative drugs and medical devices, supported by favorable government policies aimed at accelerating the approval process for new products[30]. Market Trends and Industry Insights - In the first half of 2024, the pharmaceutical manufacturing industry in China achieved revenue of RMB 1,235.27 billion, a year-on-year decline of 0.9%[23]. - The market for hyaluronic acid-based dermal fillers in China was valued at RMB 6.4 billion in 2021, with a compound annual growth rate (CAGR) of 19.7% from 2017 to 2021, and is projected to reach RMB 19.6 billion by 2026, with a CAGR of 25.0%[24]. - The market for PLA/PCL-based dermal fillers in China reached RMB 1.45 billion in 2022, with a staggering CAGR of 259.4% from 2021 to 2022, and is expected to grow to RMB 11.52 billion by 2027, with a CAGR of 31.2% from 2025 to 2027[25]. Environmental Responsibility - The total emissions of chemical oxygen demand (COD) from the Suzhou Pharmaceutical Plant (Hedong) were 0.673 tons for the first half of 2024, well below the limit of 500 mg/L[66]. - The company has implemented measures to ensure that all emissions are within the regulatory standards, reflecting a commitment to environmental responsibility[65]. - The company has established a hazardous waste storage facility exceeding 500㎡, with all necessary preventive measures in place[68]. Risk Management - The company faces potential risks including industry policy risks, technology innovation risks, and customer credit risks, which could impact future profitability[50]. - The company plans to strengthen credit transaction management and risk management training to mitigate potential bad debt losses due to customer defaults[52]. - Rising costs of production factors, including raw materials and labor, pose a risk to operational costs, prompting the company to implement lean production practices[55]. Shareholder and Governance - The company committed to ensuring that the funds raised from the non-public offering will not be used for real estate and related businesses, adhering to regulatory requirements[75]. - The company has established a three-party supervision system for the use of raised funds, ensuring compliance with investment project disclosures[75]. - The company has no significant litigation or arbitration matters during the reporting period[76].

重要内容提示： 一、说明会类型 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2024 年 8 月 28 日 披露了公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司经营 业绩、发展战略等情况，公司定于 2024 年 9 月 10 日召开 2024 年半年度业绩说 明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议，并在信息披露 规则允许的范围内就投资者普遍关注的问题进行回答。 证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-058 江苏吴中医药发展股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 公司董事长钱群山先生、财务总监孙曦先生、董事会秘书顾铁军先生、独立 董事陈亮先生（如有特殊情况，参会人员可能进行调整）。 四、投资者参加方式 （一）投资者可在 2024 年 9 月 10 日 13:30-14:30 通过互联网直接登陆上海 证券报·中国证券网（https://roadshow.cnstock.com/），在线直接参与本 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][15]. Core Viewpoints - The company is strategically positioned in the regenerative water light PDRN market, enhancing its aesthetic product matrix [2][4]. - PDRN has shown promising results in overseas markets, with significant benefits such as anti-inflammatory properties, tissue repair, and collagen regeneration [3][4]. - The domestic market for PDRN products is expected to grow significantly, as there are currently no approved Class III medical devices in this category, indicating strong potential demand [3][4]. Financial Forecasts and Valuation - Total revenue is projected to grow from 2,240 million yuan in 2023 to 4,204 million yuan in 2026, with a compound annual growth rate (CAGR) of approximately 21.83% [4][20]. - The net profit attributable to the parent company is expected to turn positive in 2024, reaching 125.10 million yuan, and further increasing to 402.72 million yuan by 2026 [4][20]. - The earnings per share (EPS) is forecasted to improve from -0.10 yuan in 2023 to 0.57 yuan in 2026, reflecting a significant turnaround in profitability [4][20]. - The price-to-earnings (P/E) ratio is projected to decrease from 81.47 in 2023 to 14.55 in 2026, indicating an improving valuation as earnings grow [4][20].

证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-052 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日、2024 年 5 月 16 日分别召开了第十一届董事会第一次会议和 2023 年年度股 东大会，审议通过了《江苏吴中医药发展股份有限公司关于拟变更公司注册资本 的议案》《江苏吴中医药发展股份有限公司关于拟修改<公司章程>部分条款的议 案》。具体内容详见公司于 2024 年 4 月 25 日、2024 年 5 月 17 日在《中国证券 报》、《上海证券报》及上海证券交易所网站上披露的《江苏吴中医药发展股份 有限公司关于拟变更公司注册资本及修订<公司章程>的公告》（公告编号：临 2024-035）。 江苏吴中医药发展股份有限公司 2024 年 7 月 22 日，公司已办理完成上述事项工商变更登记手续，并取得了 苏州市数据局换发的《营业执照》，相关信息如下： 统一社会信用代码：91320500134792998F 关于完成工商变更登记的公告 名称：江苏吴中医药发展股份有限公司 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏， ...

证券代码：600200 证券简称：江苏吴中 公告编号：2024-051 江苏吴中医药发展股份有限公司 关于卡络磺钠片首家通过仿制药一致性评价的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 近日，江苏吴中医药发展股份有限公司(以下简称"公司")全资子公司江苏 吴中医药集团有限公司下属分支机构江苏吴中医药集团有限公司苏州制药厂（以 下简称"苏州制药厂"）收到了国家药品监督管理局（以下简称"国家药监局"） 核准签发的关于"卡络磺钠片"（以下简称"该药品"或"本品"）的《药品补充 申请批准通知书》，该药品通过仿制药质量和疗效一致性评价（以下简称"仿制 药一致性评价"）。现将相关情况公告如下： 一、药品基本情况 药品名称：卡络磺钠片 受理号：CYHB2350653 通知书编号：2024B03248 剂型：片剂 规格：10mg 药品批准文号：国药准字 H20053124 注册分类：化学药品 上市许可持有人：江苏吴中医药集团有限公司苏州制药厂 药品生产企业：江苏吴中医药集团有限公司苏州制药厂 根据国家相关政策规定，对于通过仿制药一致性评价 ...

Summary of the Conference Call Company Overview - The document discusses LG Company and its recent product value proposition [1] Key Points and Arguments - LG Company has introduced new products that emphasize cost-effectiveness and quality [1] - The company aims to enhance its market position by focusing on innovative features and competitive pricing [1] Other Important Content - The discussion highlights the importance of consumer feedback in shaping product development [1] - There is a mention of LG's commitment to sustainability and eco-friendly practices in its manufacturing processes [1]

证券代码：600200 证券简称：江苏吴中 公告编号：临 2024-050 江苏吴中医药发展股份有限公司 关于部分限制性股票回购注销实施公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要内容提示： 回购注销原因： 江苏吴中医药发展股份有限公司（以下简称"公司"或"江苏吴中"）分别 于 2024 年 4 月 23 日及 2024 年 5 月 16 日召开了第十一届董事会第一次会议、第 十一届监事会第一次会议和 2023 年年度股东大会，审议通过了《公司关于回购 注销部分限制性股票的议案》。鉴于公司 2021 年限制性股票激励计划（以下简 称"本次激励计划""本激励计划"或"《激励计划》"）中 3 名首次授予激励 对象与 1 名预留授予激励对象因个人原因已离职，已不再具备限制性股票激励对 象资格，根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《江苏吴中医药发展股份有限公司 2021 年限制性股票激励计划》（以下简称"《激 励计划》"）的相关规定以及公司 2022 年第一次临时股东大会对董事会的授权， 公司将上述 ...

江苏吴中医药发展股份有限公司（以下简称"公司"）于 2018 年 8 月 20 日召开第九届董事会第二次会议，审议通过了《关于全资子公司江苏吴中医药产 业投资有限公司拟签署<南昌吴中产业升级发展基金合作协议>》的议案。（具体 见公司于 2018 年 8 月 22 日在《中国证券报》《上海证券报》及上海证券交易所 网站上披露的相关公告） 2018 年 9 月 19 日，江苏吴中医药产业投资有限公司（以下简称"医药产业 投资公司"）与江西金控投资管理中心（有限合伙）及上海中诺投资有限公司签 署了《南昌苏吴健康产业管理中心（有限合伙）合伙协议》及《南昌苏吴健康产 业管理中心（有限合伙）之入伙协议》，医药产业投资公司出资人民币 2.7 亿元 入伙南昌苏吴健康产业管理中心（有限合伙）（以下简称"南昌苏吴健康基金" 或"基金"）。（具体见公司于 2018 年 9 月 20 日在《中国证券报》《上海证券 报》及上海证券交易所网站上披露的相关公告） 2023 年 8 月 28 日，公司召开第十届董事会第八次会议，审议通过了《关于 南昌苏吴健康产业管理中心（有限合伙）拟清算退出的议案》。基于南昌苏吴健 康产业管理中心（有限合伙 ...